KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $6.3 billion.

  • Vertex Pharmaceuticals' Total Non-Current Liabilities rose 11.17% to $6.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 billion, marking a year-over-year increase of 11.17%. This contributed to the annual value of $5.1 billion for FY2024, which is 19.59% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Total Non-Current Liabilities stood at $6.3 billion, which was up 11.37% from $5.7 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Total Non-Current Liabilities peaked at $6.3 billion during Q3 2025, and registered a low of $2.8 billion during Q2 2021.
  • In the last 3 years, Vertex Pharmaceuticals' Total Non-Current Liabilities had a median value of $4.5 billion in 2024 and averaged $4.9 billion.
  • Data for Vertex Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY soared of 31.08% (in 2021) over the last 5 years.
  • Vertex Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $3.0 billion in 2021, then climbed by 17.27% to $3.6 billion in 2022, then increased by 20.26% to $4.3 billion in 2023, then grew by 19.59% to $5.1 billion in 2024, then grew by 11.17% to $6.3 billion in 2025.
  • Its Total Non-Current Liabilities stands at $6.3 billion for Q3 2025, versus $5.7 billion for Q2 2025 and $5.4 billion for Q1 2025.